4.7 Article

The mechanism of action of glatiramer acetate treatment in multiple sclerosis

Journal

NEUROLOGY
Volume 74, Issue 1, Pages S25-S30

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3181c97e39

Keywords

-

Funding

  1. Teva Neuroscience
  2. National Institutes of Health [RO1 NS 37513]
  3. National Multiple Sclerosis Society
  4. NIH/NIAID

Ask authors/readers for more resources

Objective: Glatiramer acetate (formerly known as copolymer 1) is the major noninterferon immunomodulatory agent used in the treatment of relapsing-remitting multiple sclerosis. Its mechanism of action over the past 40 years has evolved with our understanding of the immune response. Methods: We review the various mechanisms that have been proposed for this random polymer over the years, with emphasis on recent methods that utilize modern immunologic techniques. Results: Studies describing processes such as immune deviation and effects on regulatory T cells and antigen-presenting cells are presented. Conclusions: Effects of glatiramer acetate on the immune response have evolved as our technical abilities and knowledge of the immune response itself have developed. NEUROLOGY 2010; 74(Suppl 1):S25-S30

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available